São Paulo - Delayed Quote BRL

Regeneron Pharmaceuticals, Inc. (REGN34.SA)

65.74

-1.21

(-1.81%)

收市：January 31 at 5:01:58 PM GMT-3

Regeneron to Report Q4 Earnings: Is a Beat in the Cards?

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.

Zacks 17 hours ago

REGN
Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Regeneron (REGN) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks 21 hours ago

REGN
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks yesterday

HOLX

REGN
Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback

The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.

The Wall Street Journal 2 days ago

REGN
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

REGN

GSK
Drugmakers Show Restraint on Price Increases in New Trump Era

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year. The modest size of the annual increases could help companies avoid criticism of gouging from President Trump while seeking his administration’s support for such priorities as taking aim at the rebates given to middlemen and altering a federal program providing discounts to certain hospitals. Last year’s median price increase was 4.5%.

The Wall Street Journal 3 days ago

PFE

AMGN

UTHR
Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 days ago

REGN
Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options

Investors need to pay close attention to Regeneron Pharmaceuticals (REGN) stock based on the movements in the options market lately.

Zacks 3 days ago

REGN
Is Regeneron Pharmaceuticals (REGN) Among the Best Depressed Stocks to Invest in Now?

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a healthy Q4, as the equity markets were primarily aided […]

Insider Monkey 3 days ago

REGN

^GSPC
Is Regeneron Pharmaceuticals (REGN) the Best Stock to Buy and Hold for 2025?

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other best stocks to buy and hold for 2025. Stocks have been performing well lately as they seem to have been influenced […]

Insider Monkey 4 days ago

REGN
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best falling stocks to invest in right now. The overall stock market has been in an uptrend, as depicted by major […]

Insider Monkey 7 days ago

REGN
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in the 2025 Regeneron Science Talent Search (STS), the U.S.'s longest-running and most distinguished science, technology, engineering and math (STEM) competition for high school seniors.

PR Newswire 8 days ago

REGN
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES

Regeneron Canada Company today officially opened its first headquarters that will allow it to better serve the needs of Canadian patients who may benefit from its life-transforming, innovative medicines for serious diseases.

CNW Group 10 days ago

REGN
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks on Jim Cramer’s radar. Jim Cramer, host of Mad Money, recently emphasized the importance of long-term investing, urging investors to focus on […]

Insider Monkey 13 days ago

REGN
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks 14 days ago

REGN
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.

Zacks 15 days ago

REGN

NTLA

MRNA
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

MRNA and NTLA are down this week after providing financial and strategic updates.

Zacks 15 days ago

REGN

MRNA

NTLA
UBS cuts rating on Regeneron stock amid Eylea uncertainty

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

Investing.com 15 days ago

REGN
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. In one of his latest appearances on CNBC’s Squawk on the Street, Jim Cramer started the morning […]

Insider Monkey 16 days ago

REGN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...

Simply Wall St. 17 days ago

REGN

表現總覽

回報	REGN34.SA	S&P 500
年初至今	-9.76%	+2.26%
1 年	-15.72%	+22.65%
3 年	+21.35%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regeneron Pharmaceuticals, Inc. (REGN34.SA)

Regeneron to Report Q4 Earnings: Is a Beat in the Cards?

Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback

Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline

Drugmakers Show Restraint on Price Increases in New Trump Era

Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline

Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options

Is Regeneron Pharmaceuticals (REGN) Among the Best Depressed Stocks to Invest in Now?

Is Regeneron Pharmaceuticals (REGN) the Best Stock to Buy and Hold for 2025?

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?

America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

UBS cuts rating on Regeneron stock amid Eylea uncertainty

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

表現總覽